Slingshot Biosciences Welcomes Visionary Leader and Industry Expert Dr. Nimisha Srivastava as new Chief Operations Officer
Selina Yee
EMERYVILLE, Calif., December 4, 2024 – Slingshot Biosciences today announced the addition of Nimisha Srivastava, Ph.D. as Chief Operations Officer. Dr. Srivastava brings more than 20 years of experience in nanofluidics, synthetic biology technology development and operational scale-up, as well as a proven track record of building high-performing technical teams.
Dr. Srivastava’s expertise in scaling disruptive technologies will be instrumental in establishing Slingshot Biosciences’ customizable cell mimics as the gold standard in research, diagnostics and manufacturing. Prior to Slingshot, she led the scale-up of lab processes, automated workflows, and high-throughput synthetic DNA and RNA production at Twist Biosciences, where she was part of the founding engineering team. In 2021, her team launched Twist’s state-of-the-art 100,000-square-foot “Factory of the Future” production facility. Before Twist, she founded Poise Technologies, where she developed rheological sensors for cancer and cardiovascular diagnostics. She also advanced POC microfluidic pathogen detection at NVS Technologies. Dr. Srivastava holds a Ph.D. in chemical engineering from the University of Michigan, with specialized expertise in fluid dynamics and miniaturization.
“I am absolutely thrilled to join Slingshot Biosciences at such an exciting time,” said Dr Srivastava. “The company’s commitment to cell therapy and drug discovery aligns perfectly with my own values and experience and I look forward to working with the talented team to drive operational excellence and deliver value for our customers and stakeholders.”
As Chief Operating Officer, she will oversee all facets of R&D and operations, driving the development of scalable, innovative and cutting-edge technologies. Nimisha will also craft a vision that aligns the company’s operational and commercial strategy as Slingshot embarks on an exciting period of exceptional growth and expansion.
“We couldn’t be more excited to welcome Nimisha to Slingshot,” said Jeffery Kim, CEO. “Her leadership, experience, and innovative spirit make her an invaluable addition to our team, and we look forward to all we’ll achieve together.”
About Slingshot Biosciences
Slingshot Biosciences develops cell mimics for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf solution for cell-like reagents that are stable, low-cost, and targeted toward a range of indications and markets. www.slingshotbio.com.
nimisha srivastava, dr nimisha, nimisha shrivastava, slingshot biosciences, slingshot bio
Dr. Nimisha Srivastava: A Leader in Synthetic Biology
Dr. Nimisha Srivastava brings a wealth of experience in synthetic biology and nanofluidics, making her a pivotal addition to Slingshot Biosciences. Her previous role at Twist Biosciences involved leading the scale-up of automated workflows and high-throughput production, showcasing her expertise in transforming innovative ideas into operational realities.
With a strong background in engineering and a passion for advancing cell therapy, Dr. Srivastava is poised to enhance Slingshot's capabilities in developing customizable cell mimics. Her leadership will not only drive operational excellence but also foster a culture of innovation that aligns with the company's mission to revolutionize diagnostics and therapeutics.
Innovations in Cell Mimics and Their Impact on Diagnostics
Slingshot Biosciences is at the forefront of developing cell mimics that serve as versatile tools in diagnostics and therapeutics. These advanced cell-like reagents are engineered to be stable and cost-effective, providing researchers with reliable controls for various applications, including flow cytometry and biomarker analysis.
The introduction of these innovative solutions is set to transform the landscape of clinical diagnostics, enabling more accurate and efficient testing methodologies. By leveraging breakthroughs in polymer chemistry and distributed manufacturing, Slingshot aims to deliver off-the-shelf products that meet the growing demands of the healthcare industry.
Future Directions for Slingshot Biosciences
Under the leadership of Dr. Nimisha Srivastava, Slingshot Biosciences is charting a promising course for future innovations in the field of cell therapy and diagnostics. The company is committed to expanding its product offerings and enhancing operational efficiencies to better serve its customers and stakeholders.
With a focus on scaling technologies and refining processes, Slingshot aims to position itself as a leader in synthetic biology. The strategic vision includes collaborations with research institutions and industry partners to explore new applications for cell mimics, ultimately driving advancements in healthcare solutions.
The Importance of Operational Excellence in Biotechnology
Operational excellence is crucial in the biotechnology sector, where precision and efficiency can significantly impact research outcomes and product development timelines. Dr. Srivastava's role as Chief Operations Officer emphasizes the need for streamlined processes and innovative practices to enhance productivity at Slingshot Biosciences.
By implementing best practices in operations and fostering a culture of continuous improvement, Slingshot aims to ensure that its technologies are not only cutting-edge but also accessible and reliable for researchers and clinicians alike. This commitment to excellence will support the company's mission of delivering high-quality solutions in the rapidly evolving field of synthetic biology.
